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The Emerging Role of HTLV-I/II and HIV-1 Among Intravenous 
Drug Users in Detroit 
Anthony F. Ognjan, MD,* Chris A. Lewandowski, MD,* Bradley T. Belian, 
MSE, MA,* John Burczak, PhD,* Norman Markowitz, MD,* Helen Lee, PhD,* 
and Louis D. Saravolatz, MD* 
During 1987-1988, a seroprevalence study of the human immunodeficiency virus (HIV-1) and the 
human T-cell lymphoma/leukemia virus (HTLV-l/II) was performed among Detroit intravenous 
drug users unaffiliated wdh substance abuse programs. Seroprevalence data along with patient 
demographic information were compared to a similar study peiformed in 1985-1986. In the earlier 
study, 12 (12.5%) of 96 individuals tested posdive for HIV-1. Of lhe 74 available negative samples 
retested in 1987-1988 for retroviruses, 7 (9.5%) tested posdive for HTLV-I/II. Thus, the overall 
retroviral (HIV-1, HTLV-I/II)seropositive rate for 1985-1986 was 22%. In 1987-1988, 11 (15.7%) 
of 70 individuals tested positive for HIV-1 and 7 (10%) tested positive for HTLV-I/II. Concomi-
tant infection with both viruses was found in 2 (2.9%) of the 70 individuals. Thus, retrovirus sero-
prevalence in 1987-1988 was 22.9%. In 1987-1988, significant differences between the retroviral-
posiiive group and the retroviral-negative group consisted of intravenous drug use greater than 16 
years (P = 0.059) for an odds ratio of 3.80 (Cl 1.12-12.89) and sex with female prostitutes (P = 0.029) 
foran odds ratio of 5.38 (Cl 1.38-20.95). (Henry Ford Hosp MedJ 1992;40:131-5) 
One in four individuals with the acquired immunodeficien-cy syndrome (AIDS) in the United States has used illicit 
drugs (1). There are an estimated 1.1 million active intravenous 
drug users (IVDUs) in the United States, but only about 15% re-
ceive substance abuse counseling (2). A total of 90% are hetero-
sexual and 30% are women. Of the women, 90% are of child-
bearing age and 30% to 50% have engaged in sexual prostitution 
(3). They represent the major source of perinatal transmission 
of the human immunodeficiency virus (HIV-1) in the United 
States (3-7). Seroprevalence of HIV-1 among IVDUs ranges 
from less than 5% in most geographic areas of the United States 
to 60% in New York City and surrounding areas (2). 
The human T-cell lymphoma-Ieukemia virus (HTLV-I) is 
the first human retrovirus to he described. Among the general 
United States population, less than 1% are infected with HTLV-
I (8,9) which shares the same routes of transmission as HIV-1 
(10-12). In I VDU populations, however, significantly higher 
HTLV-I seroprevalence has been demonstrated. Serum speci-
mens collected in 1971-1972 from 1,129 IVDUs from 43 .states 
disclosed a seroprevalence of 6.3% (13). More recently, HTLV-
I seroprevalence among IVDUs of New York City ranged from 
9% to 23% (14,15). Since HTLV-I cannot be readily distin-
guished from HTLV-II, we will refer to these two agents collec-
tively herein as HTLV-I/II, 
In the metropolitan Detroit area, the Detroit Police Depart-
ment estimates that there are 30,000 to 40,000 active IVDUs 
(16), Despite this large I VDU population, relatively few sero-
prevalence studies for HIV-1 have been conducted, and no sero-
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prevalence studies for HTLV-I/II exist. According to available 
studies, HIV-1 seroprevalence ranged from 4.6% to 12.5% in 
1985-1986 and from 7,8% to 13,8% in 1986-1987 (2,16), 
This study was undertaken to examine the seroprevalence of 
both HIV-1 and HTLV-I/It retroviruses in the IVDU population 
of Detroit, to collect demographic and risk factor information 
forthis population for 1987-1988, and to compare this informa-
tion with a similar study performed in 1985-1986 (16), 
Methods 
Patient selection 
This study attempted to enroll all patients with an identifiable 
intravenous dmg use history who sought medical assistance in 
either Henry Ford Hospital's Department of Emergency Medi-
cine or Infectious Diseases Clinic between October 14, 1987, 
and March 28, 1988, Henry Ford Hospital is a 923-bed acute 
care facility located in the inner city of Detroit. The hospital 
maintains an active Emergency Department that services the lo-
cal area for general medical, trauma, and surgical problems. Pa-
tients were included in the study if they admitted to parenteral 
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drug abuse within the preceding five years and provided in-
formed consent before having their semm tested for HIV-1 and 
HTLV-I/II. Informed consent was provided by alt patients. Each 
was interviewed by a physician and completed an anonymous 
questionnaire detailing individual demographics and dmg, sex-
ual, social, and medical histories. Patients were excluded if they 
had previously tested positive for HIV-1 or been diagnosed with 
AIDS (Centers for Disease Control criteria). 
Serologic screening 
Collected semm was stored at -70° C along with semm col-
lected in a similar epidemiologic study performed during 1985-
1986. Serologic testing was performed in batches by the same 
laboratory technicians to minimize laboratory variability in test-
ing. Semm samples were tested for antibodies to HTLV-I/II and 
HtV-1 by enzyme immunoassay (EIA) using purified viral ly-
sate (Abbott Laboratories, North Chicago, IL). Repeatedly reac-
tive samples by EIA were confirmed by Westem Blot. Those 
EIA-positive samples that were indeterminate or negative by 
Westem Blot methodology were further tested by radioim-
munoprecipitation assay (RIPA) using 35^  methionine and cys-
teine labeled cell lysate (Abbott). Reactive samples by RIPA 
were also considered positive. 
Statistical analysis 
Variables from the questionnaire were compared for seropos-
itive and seronegative groups using Fisher's Exact test. Risk ra-
tios and 95% confidence intervals (Cts) were also calculated. 
Results 
A total of 79 IVDUs were identified and enrolled. Complete 
data (semm and completed questionnaire) were available for 70 
individuals. Patients were excluded if their questionnaires were 
incomplete or, most commonly, if they voluntarily withdrew 
from the study after attempted phlebotomy. 
A total of 74 (76%) of 96 samples collected in 1985-1986 
were available for serologic study in 1987-1988. Of the original 
96 specimens, 22 had been consumed while performing HIV-1 
serology. The 12 HIV-1 positive specimens collected during 
that study were among these 22 samples. None of the 74 remain-
ing specimens retested positive for HtV-1 in 1987-1988 (Table 
I) . 
In 1985-1986, therefore, 12 (12.5%) of 96 individuals tested 
positive for HIV-1. Of the 74 available samples retested in 
1987-1988 for retrovimses, 7 (9.5%) of 74 tested positive for 
HTLV-I/II. The minimum overall retroviral (HIV-1 4- HTLV-I/ 
II) seropositive rate for 1985-1986 is estimated to be 22% (Ta-
ble 1). 
In 1987-1988, 11 (15.7%) of 70 individuals tested positive 
for HIV-1 and 7 (10%) of 70 samples tested positive for HTLV-
I/II. Concomitant infection with both viruses was reported in 2 
(2.9%) of 70. The overall retrovims seroprevalence in 1987-
1988 was 22.9%. tn 1987-1988, significant differences between 
the retroviral-positive group and the retroviral-negative group 
consisted of intravenous drug use greater than 16 years (P = 
0.059) with an odds ratio of 3.80 (Ct 1.2-2.89) and sex with fe-
male prostitutes (P = 0.029) for an odds ratio of 5.38 (CI 1.38-
20.95) (Table 2). 
In 1987-1988, the average age was 40.6 years for the retro-
vims-positive group and 35,6 years for the retrovirus-negative 
group. The HIV-1 seropositive group consisted of 11 subjects, 
nine men and two women. The HTLV-I/II group numbered 
seven, alt men. Black men predominated in this study, reflecting 
the population served by the hospital's Emergency Department. 
In 1987-1988, 51.5% of both retroviral-positive and retroviral-
negative groups admitted past sharing of intravenous drug para-
phemaUa (9 [60%] of 15 and 26 [49%] of 53, respectively). Sex-
ual contact with other intravenous drug users did not differ be-
tween the retroviral-positive and the retroviral-negative groups 
(56.3% versus 54.7%, P > 0.05). Additionally, six ofthe retrovi-
ral-positive group and 12 of the retroviral-negative group had 
donated blood at some time in the past. Only two of the retrovi-
ral-positive group and one in the retroviral-negative group ad-
mitted to previous homosexual or bisexual contact. Other vari-
ables that were evaluated include previous illnesses, military 
service, and imprisonment. These variables were not associated 
with an increased risk of retroviral infection. 
In the 1985 survey, 8 (67%) of 12 HIV-1 positive individuals 
admitted sharing dmg paraphemalia, but only 40 (47.6%) of 84 
of the retroviral-negative group admitted the same. Prostitute 
contact occurred in 3 (25%) of 12 HIV-t positive individuals 
and 13 (15.5%) of 84 HIV-1 negative individuals. Homosexual/ 
bisexual contacts were reported by one individual in the HIV-1 
positive group and by three in the HIV-1 negative group. No 
personal data were available for the HTLV-t/II positive individ-
uals from the 1985-1986 survey. 
Discussion 
IVDUs constitute the second largest population at risk for 
AIDS (1,2,17,18). A total of 25% of patients with AIDS in the 
United States have a history of intravenous drug use. Most sero-
prevalence data among U.S. IVDUs have been obtained from 
individuals seeking treatment at drug abuse treatment facilities 
(2,18). Since only an estimated 15% of the 1.1 million IVDUs in 
the U.S. are involved with treatment, existing HIV-1 seroprev-
alence data may not be representative of IVDUs as a whote (18-
20). Both of our 1985-1986 and 1987-1988 studies were con-
ducted with active IVDUs not currentty involved in a detoxifi-
cation or substance abuse clinic. These data therefore may rep-
resent a group more likely to retum to intravenous drug use upon 
discharge from the hospital or emergency room and, for those 
carrying the retrovims, to potentially disseminate it. 
Detroit's IVDU population is on the upward slope of the epi-
demic curve of HIV-1 infection and AIDS, as has happened in 
other metropolitan areas (21). tn New York City, HIV-1 sero-
prevalence of IVDUs increased from 12% in 1978 to greater 
than 50% by 1984 (20,22). The seroprevalence among the 
IVDUs of Detroit, which increased from 12.5% in 1985-1986 to 
15.7% in 1987-1988, suggests that Detroit may be experiencing 
a similar increase of which it is not aware because of the lack of 
accurate, current estimates. It is possible that an anticipated in-
crease in HlV-1 infection could be blunted if IVDUs were in-
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Table I 
Seroprevalence of HTLV-I/II and HIV-1 in Detroit 
Positive 
HTLV-I mv-i or 
Year mv-i HTLV-I and HIV-1 HTLV-I 
1985-1986 12 of 96 (12.5%) 7 of 74 (9,5%) * 
— (22.9%) 
1987-1988 11 of70(15,7%) 7 of 70 (10.0%) 2 of 70 (2.9%) 16 of 70 (22.9%) 
*Twenly-two serum specimens from 1985-1986 were nol available for HTLV-I testing. 
creasingly aware of the AIDS epidemic from educational pro-
grams, word of mouth, or the mass media (3,20,22-24). Aware-
ness could lead to a reduction in exposure to retroviruses 
through proper cleansing or nonreuse of drug paraphernalia, 
safe sex practices, or dmg use modification (19,24-26). 
Our study suggests a prevalence of HTLV-I/II in Detroit's 
hospitalized IVDU population. Seroprevalence was 9.5% in 
1985-1986 and 10% in 1987-1988. HTLV-I has been shown to 
be endemic in southwestem Japan and further studies demon-
strated increased seroprevalence of the virus in Africa, the Ca-
ribbean, South America, and the southeastem United States (27-
29). Among IVDUs in the United States, prevalence of HTLV-I 
ranges from 6.3% (13) to 23% (15), compared to a prevalence of 
0.028% in the general population (9). In our study, coinfection 
with both HIV-1 and HTLV-I/II was found in 2.9% of IVDUs. 
The clinical implications of simultaneous HTLV-I/II and 
HIV-1 infection are unclear. Adult T-cell leukemia has been re-
ported in a homosexual male from Trinidad (30), and a T8 lym-
phoproliferative disorder has been reported (31). More recently, 
polymyositis (32) has been found in a patient infected with both 
viruses. Further, it has been reported that human peripheral 
blood lymphocytes infected with HIV-1 in vitro can be induced 
to produce large quantities of HIV-1 after mitogenic stimulation 
by HTLV-I virions (33). In theory, dually infected individuals 
may produce greater quantities of HIV-1 that may result in more 
severe (HIV-1-related) immunosuppression and enhanced facil-
ity to transmit the viruses or accelerate malignant transforma-
tion. Correspondingly, with the knowledge that both viruses are 
transmitted in a similar fashion, it is noteworthy that HIV-1 in-
fections were found in eight of 10 children in households of du-
ally infected parents and in the two spouses of dually infected 
men (34), However, no evidence of HTLV-I infection was 
found among these individuals. The difference did not seem to 
be related to lower numbers of HTLV-I-infected lymphocytes, 
as all HTLV-I positive adults had a high proportion of HTLV-t-
infected cells when compared to other HTLV-I-infected indi-
Table 2 
Demographic Information Among Intravenous Drug Users of Detroit: 1987-1988 
HIV-1 HTLV-1 
mv-i 
or 
HTLV-1 Negative 
Odds 
Rario 
95% 
Confidence 
Interval 
N = 70 11 7 16 54 
Age (years) (mean ± SD) 39.7 ±5 42.5 ±5 40,6 ± 5 35.6 ±7 
Male: Female 9:2 7:0 14:2 36:18 3.50 0.72-17.09 
Black: White 9:2 7:0 14:2 41:12 2.05 0.41-10.30 
Length IVDU (years) (mean ± SD) 13.3±7 15,1 ±7 13.3±7 10.6 ±6 
IVDU > 16 years 5/11 4/7 7/16 9/53 3.80 1.12-12.89* 
Shared paraphemalia 6/11 4/6 9/15 26/53 1.56 0.49-4.99 
Past Illness: 
Endocarditis 2/11 4/7 5/16 9/53 2.22 0.62-7.97 
Abscess 6/11 3/7 8/16 17/53 2.12 0.68-6.60 
Pneumonia 3/11 3/7 5/16 8/53 2.56 0.70-9.36 
Hepatitis B seroposirive 1/S 0/5 1/12 4/48 1.00 0.10-9.86 
Sexual Behavior: 
Sex with bisexual 0/9 2/5 2/14 1/46 2.50 0.20-31.00 
Sex with IVDU 6/11 4/7 9/16 29/53 1.06 0.35-3.28 
Sex with female prostitute 3/9 3/6 6/14 6/49 5.38 I.38-20.95t 
Other: 
Military 4/10 .V6 6/14 8/51 4.03 I.I0-I4.79t 
Prison 3/10 3/7 5/15 12/46 1/42 0.40-4.99 
Donated blood 2/10 4/6 6/15 12/51 2.17 0.64-7.33 
Received blood 4/11 4/7 7/16 17/46 1.33 0.42-4.21 
*P = 0.059. 
tP = 0.029. 
tP = 0.068. 
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viduats (34). When additional dually infected individuals are 
identified and clinical cases develop, further studies should clar-
ify the implications of coinfection with HTLV-I and HIV-1. 
The sharing of dmg paraphemalia by IVDUs has been impli-
cated in the spread of retroviruses (3,12,18,24,35). Approxi-
mately 50% of both the retroviral-positive and retroviral-nega-
tive groups in the present study admitted to sharing drug para-
phernalia. By contrast, in 1985-1986, 75% of Deti-oit's HIV-1 
positive IVDUs reported sharing paraphemalia, while only ap-
proximately 50% of the HIV-1 negative group admitted to this 
practice. Clearly, the high rate of needle/syringe sharing among 
all groups in both studies represents continued significant risk 
for retroviral transmission among IVDUs. In addition, about 
half of both retroviral-positive and retroviral-negative individu-
als report sex with other IVDUs. While sexual activity repre-
sents another avenue for potential retroviral spread among the 
IVDU population, non-IVDU sexual partners among Detroit's 
IVDUs are clearly also at risk. 
A significantiy greater percentage of retroviral-positive indi-
viduals in 1987-1988 had contact with female prostitutes (48% 
versus 12%, P = 0.0288), while prostitute contact was not asso-
ciated with retroviral infection in 1985-1986. Although reasons 
for this difference are unknown, the implications are that prosti-
tutes can become an important reservoir for transmission not 
only for their sexual partners but for their children as well. 
Certain limitations exist in comparing the present study with 
that of 1985-1986. Since the latter survey involved hospitalized 
individuals, there may exist a selection bias for "sicker" IVDUs 
who may represent a population more likely to be seropositive. 
Therefore, it is possible that the apparent small increase in the 
HIV-1 prevalence reported in the current study underestimates 
the tme change that would occur if the groups were strictly com-
parable. Demographic information is not available for any of the 
HTLV-I/II positive individuals in 1985-1986 nor is HTLV-I/II 
seroprevalence available from the 22 HIV-1 positive individu-
als for that study. This information would be valuable in profil-
ing more completely the retroviral-positive (HIV-1, HTLV-I/lt) 
groups of 1985-1986. 
Another selection bias introduced in the study was the exclu-
sion of known HIV-positive or AIDS cases. This was consistent 
with the effort to establish the prevalence of unknown HIV 
cases. Because a community survey of IVDUs cannot be done 
without significant danger to the researchers, the bias of study-
ing only hospitalized patients was accepted in order to estimate 
the prevalence of retroviral infection among IVDUs. 
Containing and controlling communicable diseases is a desir-
able public health goal. Studies of retrovims among high-risk 
groups in nonepidemic settings are necessary to plan for future 
health care needs as well as to determine the resources required 
for educational programs that may help halt further transmis-
sion. 
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